Want to take quizzes and track your credits?
Are the interventions to prevent taxane-induced dermatologic adverse events in patients undergoing chemotherapy safe and effective?
In this systematic review of 34 reports, most studies of taxane-induced alopecia supported the use of cold caps or scalp cooling systems to reduce hair loss. Relevant evidence also indicated that use of frozen gloves and socks was associated with the prevention of taxane-induced nail and skin changes.
Use of cold caps or scalp cooling systems and frozen gloves and socks may be effective in the prevention of taxane-induced alopecia as well as nail and cutaneous hand toxic effects; further investigation is needed to establish the routine usage protocols, standard outcome measures, and long-term efficacy and safety for these interventions.
Chemotherapy-induced alopecia as well as nail and cutaneous changes occur in up to 89% of patients receiving taxane-based chemotherapy and are associated with cosmetic concerns, psychosocial distress, and overall morbidity.
To review the efficacy and safety of interventions to prevent taxane-induced dermatologic adverse events.
PubMed and Scopus databases were systematically reviewed for studies published in the English language from January 1, 1980, to August 13, 2018. Specific search terms included but were not limited to taxane, docetaxel, paclitaxel, prevent, nail, skin, hair, alopecia, and onycholysis. Primary clinical studies that detailed preventive interventions for taxane-induced dermatologic adverse events and that classified results according to a taxane-specific chemotherapy regimen were reviewed and graded according to a 5-point scale, modified from the Oxford Centre for Evidence-based Medicine.
The 34 original reports that met the inclusion criteria consisted of 6 randomized clinical trials, 4 nonrandomized clinical trials, 18 cohort studies, 3 case-control studies, 1 cross-sectional study, and 2 case reports and involved a total of 5647 unique participants. A total of 22 studies addressed preventive interventions for alopecia associated with taxane use, whereas 12 studies focused on taxane-induced skin and nail changes. Specifically, 20 (95%) of 21 studies supported the use of either a cold cap or a scalp cooling system to reduce alopecia but reported substantial differences in efficacy depending on the chemotherapy regimen. Scalp cooling was generally considered safe by all pertinent studies despite a single report of scalp skin metastasis. Similarly, use of frozen gloves and frozen socks in the prevention of nail and cutaneous hand and foot toxic effects was considered safe in 7 (88%) of 8 studies, although discomfort was common and frostbite was noted in 1 patient. Overall, use of frozen gloves was endorsed by 4 (67%) of 6 studies to prevent nail toxic effects and by 3 (60%) of 5 studies to prevent cutaneous hand changes.
Conclusions and Relevance
Scalp hypothermia with cold caps or scalp cooling systems has demonstrated efficacy as a monotherapy in preventing taxane-induced alopecia, and use of frozen gloves and socks has been associated with reduced nail and skin changes. Future studies should establish the routine usage protocols, standard outcome measures, and long-term efficacy and safety for these interventions.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Accepted for Publication: August 16, 2018.
Corresponding Author: Adam Friedman, MD, The George Washington University School of Medicine and Health Sciences, 2150 Pennsylvania Ave, NW, Second Floor, Washington, DC 20037 (firstname.lastname@example.org).
Published Online: October 31, 2018. doi:10.1001/jamadermatol.2018.3465
Author Contributions: Dr Friedman and Mr Marks had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: All authors.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Marks, Qureshi.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Marks.
Supervision: Marks, Friedman.
Conflict of Interest Disclosures: Dr Friedman reported serving as a consultant to Dermira, Eli Lilly and Company, Encore Dermatology Inc, Exeltis, Galderma, IntraDerm, Johnson and Johnson, Oculus Innovative Sciences, Pfizer Inc, and Sanovaworks as well as receiving honoraria from Allergan, Amgen, Bayer, Biogen, Janssen Biotech, La Roche-Posay Laboratorie Pharmaceutique, Medscape, Menlo Therapeutics, Novartis, Orlando Dermatology Aesthetic & Clinical, Promius Pharma, Regeneron, Sanovaworks, and Valeant Pharmaceuticals. No other disclosures were reported.
You currently have no searches saved.